Macrophages are found in the pregnant uterus and placenta (1, 2) . These cells have been suggested to play many roles during pregnancy including the synthesis of monokines, such as tumor necrosis factor a (TNF-a) and interleukin 1 (IL-1) (2-4), the synthesis ofimmunosuppressive factors, and phagocytosis of debris and microbial invaders (2) . In the mouse placenta, fetally derived macrophages contribute a significant portion of labyrinthine mesenchymal cells and cells of the chorionic villous stroma (2, 5) . Macrophages have been detected by day 10 of pregnancy with significant numbers of morphologically matured macrophages, displaying the mononuclear-phagocytic-specific cell surface antigen F4/80 by day 12 (5) . Although these placental macrophages were shown to be phagocytic, other functions remain to be demonstrated.
An important immunological function of macrophages is to activate T cells by serving as antigen-presenting cells and initiate an immune response (6) . One previous report, however, has shown that placental macrophages are unable to initiate an efficient immune response against Listeria monocytogenes (7) . To study the immunological function of placental macrophages, we have obtained a highly enriched primary placental macrophage population. In addition, we have isolated and characterized three macrophage cell lines from day 12 and 13 placentas. Our study shows that placental macrophages at this stage ofdevelopment, despite expressing class II molecules, have a diminished ability to present protein antigens to T-cell hybridomas.
MATERIALS AND METHODS Mice. BALB/c, C57BL/6, and A.CA mice were purchased from The Jackson Laboratory. BALB/k mice were provided by F. Lilly (Albert Einstein College of Medicine).
Reagents. Ovalbumin (OVA), keyhole limpet hemocyanin (KLH), cytochrome c (cytc), hen egg lysozyme (HEL), and staphylococcal enterotoxin B (SEB) were purchased from Sigma. Trypsin-digested OVA and HEL fragments were generated by a published procedure (8 T-cell hybridomas were gifts either from J. Kappler and P. Marrack (National Jewish Center, Denver) or from S. MacPhail (North Shore University Hospital). The IL-2-dependent CTLL-2 cell line was a gift from G. Ju (Hoffmann-La Roche) (11) .
Assays. The lysozyme content in the supernatant of macrophage cultures was assayed as described (9) . placental cells to secrete TNF-a and IL-1 after lipopolysaccharide (LPS; List Biological Laboratories, Campbell, CA) stimulation was determined as described (13, 14) . The cathepsin D content of macrophage cell lysates was assayed as described (15) . Fc-receptor expression and Fc-receptormediated phagocytosis were determined as described (9 (16) and probed with a 32P-labeled Efd cDNA fragment (gift from D. R. Germain, National Institute of Allergy and Infectious Diseases, Bethesda, MD). Northern blot analysis of total cellular RNA was performed as described (16) and probed with a 32P-labeled trophoblastspecific marker, A4311 cDNA fragment (17). The same blot was then stripped by boiling in ix standard saline citrate (SSC) and probed again with 32P-labeled murine CD14 cDNA fragment (18) .
RESULTS
Analysis of the Antigen-Presenting Activity of Primary Placental Macrophages. There are three placental cell types, macrophages, decidual cells, and trophoblasts, that have receptors for CSF-1 and can potentially proliferate in response to CSF-1 (19) . However, cells harvested after 1 month of culturing of 14-day placentae isolated from a (BALB/c x BALB/k)F1 embryo in CSF-1-containing medium, express the macrophage-specific cell surface antigen detected with the antibody F4/80 and express major histocompatibility complex (MHC) class II molecules (Fig. 1) . The level ofMHC class II expression is similar to that of splenic macrophages (data not shown). This population was used as a source of primary placental macrophages. The antigen-presenting activity of primary placental macrophages was examined and compared to that of adult primary splenic macrophages. Table 1 shows that primary placental macrophages display a decreased ability to present whole protein antigens. However, they can present trypsin-digested OVA fragments to T cells. Since the majority of macrophages in the mouse placenta at this stage ofgestation are offetal origin (5, 20) , the defect in antigen presentation we have observed may reflect the developmental stage of these macrophages. We therefore examined antigen presentation by macrophages derived from fetal liver of same gestational age obtained by the same method that was used for the generation of placental macrophages. Our results indicate that fetal liver macrophages are also deficient in their ability to present whole protein antigens (Table 1) . To further analyze the antigen-presenting function ofplacental macrophages, we derived two cell lines, 2.3 and SUPL2, from primary placental macrophage cultures by transforming cells with an origin-defective SV40 DNA (9) . In addition, we also derived a cell line, JPL2A, by spontaneous transformation of a primary placental cell culture of a different genetic background (10) .
Characterization of the Cell Lines. RNA analyses showed that all three cell lines are negative for the trophoblast markers A4311 and cytokeratin but express vimentin (10) and the myeloid cell marker CD14 (21) . In addition, all of the clones express the macrophage-specific F4/80 determinant and Mac-i on their cell surface (10) , and >99% of the cells of each clone express Fc receptors, can perform Fc-receptormediated phagocytosis, and secrete lysozyme. All the characteristics of these macrophage cell lines are summarized in Table 2 . Since placental decidual cells do not express Mac-1 and F4/80 determinant, these results strongly suggest that these clones are not decidual cells but are of the macrophage lineage.
As the placenta contains cells of both maternal and fetal origin, we examined the origin of these cell lines. The 2.3 and SUPL2 cell lines were generated from a BALB/c female carrying a (BALB/c x BALB/k)F1 fetus. The genotype of these clones can, therefore, be determined by the polymorphism of the class II Ef3 gene (22) . Southern blot analysis of EcoRI-digested 2.3 and SUPL2 genomic DNA, hybridized with Ef3 cDNA probe, showed that both contain a 2.1- (Fig. 2) . These data indicate that both 2.3 and SUPL2 are of fetal origin. Since the JPL2A cell line was generated from a C57BL/6 mouse, we cannot determine whether it is of fetal or maternal origin. Fig. 3 ( Table 3 ). Reduced antigen presentation by placental macrophages is not due to the release of any suppressive factor since the coculture of placental macrophages with splenic or peritoneal macrophages does not lead to decreased activation of T-cell hybridomas (data not shown).
Although 2.3 and SUPL2 have a decreased ability to present whole protein antigens, they do present trypsindigested antigenic fragments to Ad-and Ak-restricted T-cell hybridomas (Table 4 ). This result suggests that they might have defects in their antigen-processing compartment. The DO11.10 T cell has been shown (23) to recognize an OVA fragment generated from a cathepsin D digest. We therefore assayed intracellular cathepsin D activity and found that SC8, 2.3, and SUPL2 have equivalent activity, 3.2 units, 6.8 units, and 4.0 units per million cells, respectively.
In contrast to 2.3 and SUPL2, JPL2A cells present neither OVA nor trypsin-digested OVA fragments to BO-97.10 T cells, which recognize these fragments presented on the surface of peritoneal macrophages of C57BL/6 origin. The addition of the IL-1 or peritoneal macrophages of the A.CA mouse, which by themselves cannot present OVA to BO-97.10 T cells, does not compensate this defect (Table 4) .
We also examined the ability of lines 2.3 and SUPL2 to present superantigen, which does not require processing. Superantigens have been shown to bind class II molecules outside the antigen-binding groove (24) . This interaction can then lead to the activation of a large number of T cells with T-cell receptors encoded by a single or restricted number of f3 chain variable region genes (25) . Fig. 4 shows that both 2.3 and SUPL2 cells have a decreased ability to present the superantigen SEB to the SEB-reactive T-cell hybridoma DO11.10.
DISCUSSION
Fetal macrophages are among the earliest hemopoietic cells to be produced during development and they are relatively abundant in fetal tissue and placenta (20) . To understand the function ofplacental macrophages, we have obtained a nearly homogeneous placental macrophage population and have also derived several cell lines from placental macrophage cultures. Phenotypic analysis indicated that all clones are macrophages, not decidual cells or trophoblasts. They all Experiments: A, DO11.10 T cells-an Ed-restricted and OVA-specific T-cell hybridoma; B, KHEL25.14 T cells-an Ak-restricted and HEL-specific T-cell hybridoma; C, B097.10 T cells-an Ab-restricted and OVA-specific T-cell hybridoma (for details, see Table 1 ). OVA at 1 mg/ml, HEL at 0.25 mg/ml, and trypsin-digested fragments at 0.25 mg/ml were used. APC, antigen-presenting cell. JPL2A cells, on the other hand, have defects in presenting both whole and enzymatically digested protein antigens. This defect is not due to the lack of IL-1 secretion or any other costimulatory factors (28) . This result suggests that there may be a functional heterogeneity among primary placental cells, and this heterogeneity probably is not detected in the bulk placental culture.
The mechanism for protecting the fetus from maternal immunological rejection is likely to be multifactorial, including humoral and cellular factors. Fetal liver 'y/6+ T cells that exhibit cytotoxic activity toward maternal T cells have been identified, and these cells may function to destroy the invading maternal T cells (29) . Our results imply that the decreased antigen presentation of placental/fetal macrophages may serve as another mechanism to prevent the allogeneic response of maternal T cells and may also explain the lack of macrophage bactericidal activity during uteroplacental infection (7) . These placental macrophage cell lines provide a useful system to study antigen processing at the molecular and cellular levels.
